Utrecht, The Netherlands
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences.
We are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.
Our goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.
NTrans Technologies wins the AXON Innovation for Health Award 2017 On Thursday 16 February during the fourth edition of the annual Innovation for Health conference in WTC Rotterdam, Marco de Boer of NTrans Technologies won the AXON Innovation for Health Award 2017 for the best innovation pitch presentation. NTrans Technologies